Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis (ITALY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04563286|
Recruitment Status : Unknown
Verified September 2020 by Gianluca Di Bella, University of Messina.
Recruitment status was: Recruiting
First Posted : September 24, 2020
Last Update Posted : September 24, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Specific, standardized, comprehensive, universally accepted Patient-Reported Outcome Measures (PROMs) are currently lacking for variant and wild-type cardiac amyloid transthyretin amyloidosis (v-ATTR/wt-ATTR). Our goal is then to create two scores able to provide a cumulative assessment of cardiac involvement, peripheral neuropathy (in v-ATTR), and comorbidities, and their impact on the quality of life.
In the setting of a nationwide collaboration involving 5 main Italian referral centers for this condition (in Ferrara, Florence, Pavia, Pisa and Messina), a panel will be created, including experts of ATTR cardiomyopathy, neurologists, geriatricians, health management specialists, as well as patients with either variant or wild-type ATTR cardiomyopathy (n=50).
The most clinically relevant domains for patients (such as physical limitations, symptoms, self-efficacy and knowledge, social interference, quality of life, age-related issues, social and family environment, frailty, comorbidities) will be identified. Two sets of 30 items (one for variant and another for wild-type ATTR cardiomyopathy) will be created in collaboration with patients. Questions will be formatted for gender neutrality, clarity, interpretability, and possible foreign language translations. PROMs scores will be validated through administration to around 250 consecutive outpatients. Score performance will be evaluated in terms of internal consistency, response to clinical changes, comparison with conventional clinical measures. The time needed for completion, the clarity of questions and the need for assistance from a family caregiver will be evaluated.
This project will hopefully lead to the identification of disease-specific metrics that may serve as a clinically meaningful outcome in cardiovascular research, patient management, and quality assessment.
|Condition or disease||Intervention/treatment|
|Transthyretin Amyloidosis||Other: questionnaire on life quality|
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis: The Impact of Transthyretin Amyloidosis on Life qualitY (ITALY) Study|
|Actual Study Start Date :||February 22, 2020|
|Estimated Primary Completion Date :||April 22, 2022|
|Estimated Study Completion Date :||June 22, 2022|
- Other: questionnaire on life quality
Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
- reliability [ Time Frame: baseline to 6 months ]internal consistency
- responsiveness [ Time Frame: baseline to HF hospitalization (<6 months) ]changes in scores in response to clinical changes
- validity of each domain [ Time Frame: baseline to 6 months ]comparison of scores with other measures that quantify similar concepts, namely other score points, NYHA class, 6MWD, or objective measures of cardiac dysfunction, i.e. circulating levels of NT-proBNP and hs-TnT)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
Patients with cardiac ATTR amyloidosis, either biopsy proven or diagnosed according to the algorithm for nonbiopsy diagnosis of ATTR cardiomyopathy (Gillmore et al., 2016), will be evaluated.
PROMs for v-ATTR and wt-ATTR will be created in close collaboration with 50 patients suffering from ATTR cardiomyopathy (see below), and will be validated on a cohort of 250 patients (i.e., 50 patients from each participating center; see below).
- Diagnosis of cardiomyopathy due to ATTR amyloidosis, diagnosed by endomyocardial biopsy or on the basis of the algorithm for the non-invasive diagnosis of cardiac ATTR amyloidosis (Gillmore et al., 2016).
- Clinical stability, defined as the lack of unscheduled hospitalizations and/or significant changes in cardiac therapies from at least 1 month.
- Lack of informed consent.
- Inability of understanding a written text in Italian.
- Absence of the conditions of clinical stability, as defined above.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04563286
|Università di Ferrara||Recruiting|
|Contact: Claudio Rapezzi +390532293111 email@example.com|
|Contact: Francesco Cappelli, MD +39 055 794 9946 firstname.lastname@example.org|
|Sub-Investigator: Francesco Cappelli, MD|
|Principal Investigator: Federico Perfetto|
|Università di Messina||Recruiting|
|Contact: Gianluca Di Bella +393205506147 email@example.com|
|Università di Pavia||Recruiting|
|Contact: Giovanni Palladini +390382989898 firstname.lastname@example.org|
|Fondazione Toscana Gabriele Monasterio (FTGM)||Recruiting|
|Pisa, Italy, 56124|
|Contact: Michele Emdin +393454744053 email@example.com|
|Sub-Investigator: Claudio Passino, MD|
|Responsible Party:||Gianluca Di Bella, Professor, University of Messina|
|Other Study ID Numbers:||
|First Posted:||September 24, 2020 Key Record Dates|
|Last Update Posted:||September 24, 2020|
|Last Verified:||September 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
quality of life
Amyloid Neuropathies, Familial
Heredodegenerative Disorders, Nervous System
Nervous System Diseases
Peripheral Nervous System Diseases
Genetic Diseases, Inborn
Metabolism, Inborn Errors